Quest Diagnostics Incorporated

NYSE:DGX

Medical - Diagnostics & Research

Healthcare
$259.69 -1.72%

-$3.41 today

Market cap
$28.57B
Beta
0.59
P/E (TTM)
20.9
EPS (TTM)
$9.31
Dividend yield
1.68%
52W Low $164.65High $213.50

Volume 1.30M

Average 0.91M

DGX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Quest Diagnostics IncorporatedNYSE: DGX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA growth accelerates

Q3 FY2026 EBITDA of $624M rose 14.1% year over year, ahead of the +7.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • EBITDA amounted to 19.9% of revenue in FY2025, up 0.7 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 13 analysts of $2.52B (+14.7%) for the fiscal year ending Dec 2026, a slowdown from the +15.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$624M+5.9% QoQ
Last fiscal yearDec 2025
$2.19B+15.8% YoY
LTMSep 2026
$2.3B+7.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.1%+12.9%-1.1 pp
1 year+15.8%+14.7%-1.2 pp
3-year CAGR+6.4%+7.8%+1.3 pp
5-year CAGR+6.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
2.19B USD
Year-over-year change
+15.8%
4-year CAGR
-8.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DGX compares with its peers on the latest reported figures

  • DGX's LTM Sep 2026 EBITDA of $2.3B is the highest of the 9 companies compared; the peer median is $499.29M.
  • Its year-over-year change of +7.7% is the 4th highest of 9, against a peer median of -1.7%.
  • EBITDA amounts to 19.4% of revenue for DGX, versus a peer median of 28.3%.
DGX Competitors Peer median
EBITDA for DGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DGXQuest Diagnostics IncorporatedLTM Sep 2026$2.3B +7.7%+6.4%19.4%
LHLabcorp Holdings Inc.LTM Jun 2026$2.15B +15.0%+1.0%15.0%
ILMNIllumina, Inc.LTM Jun 2026$1.36B -23.6%—30.3%
RVTYRevvity, Inc.LTM Jul 2026$767M -6.7%-13.5%26.3%
QGENQiagen N.V.LTM Jun 2026$703.39M -1.6%-2.7%33.5%
RDNTRadNet, Inc.LTM Sep 2026$295.2M -1.7%-3.0%12.4%
NTRANatera, Inc.LTM Jun 2026-$178.71M +15.6%—6.6%
GRALGRAIL, Inc.LTM Jun 2026-$374.1M +10.8%—226.4%
GHGuardant Health, Inc.LTM Sep 2026-$441.45M -24.7%—34.5%
Peer median (excluding DGX) $499.29M-1.7%-2.9%28.3%

Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.79B9.88B9.25B9.87B11.04B
Cost of Revenue6.58B6.45B6.2B6.63B7.51B
Gross Profit4.21B3.43B3.07B3.24B3.52B
Gross Margin39.0%34.7%33.2%32.9%31.9%
Research & Development00000
Selling, General & Admin1.73B1.87B1.62B1.77B1.97B
Operating Expenses1.83B2.01B1.81B1.9B1.92B
Depreciation & Amortization408M437M439M493M570M
EBITDA3.16B1.82B1.73B1.89B2.19B
EBITDA Margin29.3%18.4%18.7%19.2%19.9%
Operating Income2.38B1.43B1.26B1.35B1.6B
Operating Margin22.1%14.4%13.6%13.6%14.5%
Interest Income1M10M11M25M13M
Interest Expense152M148M163M226M277M
Other Income / Expenses296M(149M)(106M)(152M)(243M)
Income Before Tax2.68B1.28B1.16B1.19B1.36B
Pre-Tax Margin24.8%12.9%12.5%12.1%12.3%
Income Tax Expense597M264M248M273M314M
Net Income2B946M854M871M992M
Net Margin18.5%9.6%9.2%8.8%9.0%
EPS (Basic)15.908.127.597.808.87
EPS (Diluted)15.537.987.527.698.75
Weighted Avg Shares125M116M112M111M111M
Weighted Avg Shares (Diluted)128M118M113M113M113M

Quest Diagnostics Incorporated

NYSE:DGX

Intrinsic Alpha fair value

Locked

Current Price

$259.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.